JSP Pharmaceutical Manufacturing (Thailand) Public Company Limited

As of June 30, 2026, JSP Pharmaceutical Manufacturing (Thailand) Public Company Limited carries a market capitalization of 830.51M, placing it among publicly traded companies globally. Its enterprise value stands at 1.20B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, JSP Pharmaceutical Manufacturing (Thailand) Public Company Limited has 474.57M shares outstanding.

As of June 30, 2026, JSP Pharmaceutical Manufacturing (Thailand) Public Company Limited trades at a trailing price-to-earnings ratio of 19.50. The price-to-sales ratio is 0.87, and the price-to-book ratio stands at 0.93.

As of June 30, 2026, JSP Pharmaceutical Manufacturing (Thailand) Public Company Limited trades at an EV/EBITDA multiple of 7.70 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 1.25 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 13.70 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 1.20B versus a market cap of 830.51M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, JSP Pharmaceutical Manufacturing (Thailand) Public Company Limited maintains a current ratio of 1.27, meaning it holds 1.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 42.39, indicating elevated leverage, while an interest coverage ratio of 9.20 demonstrates adequate ability to service its debt obligations.

Over the twelve months ended June 30, 2026, JSP Pharmaceutical Manufacturing (Thailand) Public Company Limited posted a return on equity (ROE) of 4.80, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 2.45 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 3.09, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 5.41, useful for judging operating efficiency across full business cycles. The company generates approximately 2.21M in revenue per employee across its workforce of 434.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 4.62 indicates how many times JSP Pharmaceutical Manufacturing (Thailand) Public Company Limited sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, JSP Pharmaceutical Manufacturing (Thailand) Public Company Limited recorded 46.68M in income tax expense. That works out to an effective tax rate of 65.36, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 71.42M, leaving 42.92M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, JSP Pharmaceutical Manufacturing (Thailand) Public Company Limited's stock has declined approximately 0.58% over the past 52 weeks. The 50-day moving average sits at 1.74, while the 200-day moving average is 1.84.

Over the twelve months ended June 30, 2026, JSP Pharmaceutical Manufacturing (Thailand) Public Company Limited generated 957.03M in revenue and converted that into 42.92M in net income, yielding earnings per share of 0.05. EBITDA reached 155.50M, while operating income came in at 89.18M.

As of June 30, 2026, JSP Pharmaceutical Manufacturing (Thailand) Public Company Limited holds 42.84M in cash and equivalents against 388.03M in total debt, resulting in a net debt position of 293.04M. Total book value stands at 894.02M, with working capital of 68.87M providing operational flexibility.

JSP Pharmaceutical Manufacturing (Thailand) Public Company Limited produced 117.85M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -278.61M in capital expenditures, free cash flow totaled -160.76M - equivalent to -0.34 per share.

Over the twelve months ended June 30, 2026, JSP Pharmaceutical Manufacturing (Thailand) Public Company Limited posted a gross margin of 38.38, reflecting its pricing power and cost economics. The operating margin of 9.32 and net profit margin of 4.49 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, JSP Pharmaceutical Manufacturing (Thailand) Public Company Limited paid dividends of 0.10 per share. The dividend payout ratio of 709.83 exceeds 100%, meaning the company is distributing more than it earns and funding the dividend from cash reserves, asset sales, or borrowing, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield is negative at -19.21: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -19.83, meaning JSP Pharmaceutical Manufacturing (Thailand) Public Company Limited raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, JSP Pharmaceutical Manufacturing (Thailand) Public Company Limited has an Altman Z-Score of 1.96, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.